Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.

Published

Journal Article

Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.

Full Text

Duke Authors

Cited Authors

  • Jones, DI; McGee, CE; Sample, CJ; Sempowski, GD; Pickup, DJ; Staats, HF

Published Date

  • July 5, 2016

Published In

Volume / Issue

  • 23 / 7

Start / End Page

  • 648 - 651

PubMed ID

  • 27146001

Pubmed Central ID

  • 27146001

Electronic International Standard Serial Number (EISSN)

  • 1556-679X

International Standard Serial Number (ISSN)

  • 1556-6811

Digital Object Identifier (DOI)

  • 10.1128/CVI.00216-16

Language

  • eng